HB
HBIO.US Harvard Bioscience Inc
- Market cap
- USD 42.9M
- P/E
- -
- P/B
- 8.49x
- ROE
- -233.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HBIO.US undervalued?
Graham numberThe Graham number of Harvard Bioscience Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harvard Bioscience Inc fundamental analysis
No fundamental analysis for Harvard Bioscience Inc yet.
Harvard Bioscience Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and pr…
Full company profileHarvard Bioscience Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harvard Bioscience Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 105M | 102M | 121M | 116M | 102M | 119M | 113M | 112M | 94.1M | 86.6M | 87.6M |
| Gross Profit | 48.4M | 47.6M | 63.2M | 64.3M | 58.0M | 67.7M | 60.8M | 66.1M | 54.8M | 45.9M | 49.6M |
| Operating Income | -3.00M | -101K | 984K | 377K | 221K | 2.07M | -6.93M | 1.89M | -6.21M | -629K | -3.00M |
| EBITDA | 1.80M | 1.00M | 5.38M | 7.64M | 5.17M | 9.02M | 944K | 8.03M | -1.30M | -46.5M | -5.77M |
| Net Income | -4.31M | -865K | -3.46M | -4.69M | -7.81M | -288K | -9.52M | -3.42M | -12.4M | -56.7M | -11.9M |
| EPS | -1.26 | -0.25 | -0.95 | -1.24 | -2.02 | -0.07 | -2.30 | -0.81 | -2.85 | -13 | -2.62 |
| Balance Sheet | |||||||||||
| Total Assets | 108M | 109M | 168M | 165M | 156M | 162M | 145M | 137M | 127M | 80.1M | 75.3M |
| Total Liabilities | 35.6M | 28.5M | 85.9M | 83.2M | 79.6M | 78.9M | 73.1M | 64.3M | 63.3M | 66.3M | 70.2M |
| Shareholders' Equity | 72.2M | 80.9M | 82.2M | 81.7M | 76.7M | 83.4M | 72.2M | 73.1M | 63.3M | 13.7M | 5.11M |
| Cash & Short-term Investments | 5.60M | 5.73M | 8.17M | 8.34M | 8.32M | 7.82M | 4.51M | 4.28M | 4.11M | 8.61M | 4.86M |
| Total Debt | 13.7M | 11.7M | 60.8M | 64.5M | 57.6M | 57.0M | 54.2M | 42.8M | 44.5M | 44.3M | 44.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.38M | 1.06M | 2.34M | 8.05M | 9.33M | 1.26M | 1.15M | 14.0M | 1.44M | 6.73M | -783K |
| Capital Expenditure | 1.48M | 890K | 986K | 1.22M | 1.15M | 1.20M | 1.59M | 2.31M | 3.26M | 1.11M | 2.72M |
| Free Cash Flow | 3.90M | 167K | 1.36M | 6.83M | 8.18M | 67.0K | -438K | 11.7M | -1.82M | 5.62M | -3.50M |
| Ratios | |||||||||||
| ROE | -6.0% | -1.1% | -4.2% | -5.7% | -10.2% | -0.3% | -13.2% | -4.7% | -19.6% | -412.8% | -233.9% |
| ROA | -4.0% | -0.8% | -2.1% | -2.8% | -5.0% | -0.2% | -6.5% | -2.5% | -9.8% | -70.8% | -15.9% |
| Net Profit Margin | -4.1% | -0.8% | -2.9% | -4.0% | -7.6% | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% | -13.6% |
| Debt to Equity | 0.19x | 0.15x | 0.74x | 0.79x | 0.75x | 0.68x | 0.75x | 0.59x | 0.70x | 3.22x | 8.68x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Harvard Bioscience Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.63M | 0.39 | - |
| 2021 | USD 200K | 0.05 | - |
| 2020 | - | - | - |
| 2019 | USD 221K | 0.06 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Mar 16, 2026.
Who owns Harvard Bioscience Inc
- Insiders 9.61%
- Institutions 43.03%
- Public & others 47.36%
- Shares outstanding 4.57M
- Free float 3.69M
Top funds holding HBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 123K | 2.70% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 21.4K | 0.47% | -3.98% | Sep 2026 |
| Acuitas US Microcap Institutional | 13.4K | 0.29% | +52.34% | Jun 2026 |
| Fidelity Total Market Index | 7.02K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 5.95K | 0.13% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 4.11K | 0.09% | 0.00% | Sep 2026 |
| Gabelli Global Mini Mites I | 4.00K | 0.09% | 0.00% | Jun 2026 |
| Dimensional US Sustainability Core 1 ETF | 1.90K | 0.04% | 0.00% | Oct 2026 |
| DFA US Core Equity Class F | 1.72K | 0.04% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 1.70K | 0.04% | 0.00% | Aug 2026 |
| DFA US Vector Equity Class F | 1.70K | 0.04% | 0.00% | Aug 2026 |
| Dimensional US Small Cap ETF | 1.37K | 0.03% | 0.00% | Oct 2026 |
| DFA U.S. Vector Equity I | 1.23K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.22K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 1.03K | 0.02% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 1 ETF | 928.00 | 0.02% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 928.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding HBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Weber Capital Management LLC | 300K | 6.56% | -3.55% | Sep 2026 |
| Meros Investment Management, LP | 183K | 4.00% | +54.40% | Jun 2026 |
| Acadian Asset Management LLC | 180K | 3.93% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 170K | 3.71% | +3.87% | Jun 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 143K | 3.13% | +21.77% | Jun 2026 |
| Corsair Capital Management LLC | 123K | 2.69% | -1.60% | Jun 2026 |
| Two Sigma Investments LLC | 115K | 2.50% | +0.38% | Jun 2026 |
| Renaissance Technologies Corp | 94.3K | 2.06% | -5.03% | Sep 2026 |
| BlackRock Inc | 61.8K | 1.35% | -0.63% | Jun 2026 |
| Geode Capital Management, LLC | 47.6K | 1.04% | -20.09% | Jun 2026 |
| Mink Brook Asset Management LLC | 33.4K | 0.73% | 0.00% | Jun 2026 |
| Millennium Management LLC | 32.6K | 0.71% | -29.60% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 27.7K | 0.61% | 0.00% | Jun 2026 |
| Essex Investment Management Company, LLC | 27.0K | 0.59% | -0.18% | Jun 2026 |
| Williams & Novak LLC | 20.9K | 0.46% | -22.56% | Jun 2026 |
| UBS Group AG | 17.6K | 0.38% | +109.17% | Jun 2026 |
| RBF LLC | 16.0K | 0.35% | 0.00% | Jun 2026 |
| State Street Corp | 14.9K | 0.33% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 14.0K | 0.31% | -41.33% | Jun 2026 |
| Citadel Advisors Llc | 13.3K | 0.29% | 0.00% | Jun 2026 |
Harvard Bioscience Inc company profile
- Company name
- Harvard Bioscience Inc
- Ticker
- HBIO.US
- Exchange
- USA Stocks
- Listed since
- Dec 7, 2000
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 316
- Fiscal year end
- December
- Address
- 84 October Hill Road, Holliston, MA, United States, 01746
- Phone
- 508 893 8999
- Website
- harvardbioscience.com
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Harvard Bioscience Inc management
6- Mr. John DukePresident, CEO, Director & Member of Scientific Advisory Board · born 1971
- Mr. Mark T. FrostCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · born 1963
- Ms. Lori PackerVice President of Global People Operations
- Mr. David PanzarellaSenior Vice President of Commercial
- Kathryn FlynnCorporate Controller
- David SiroisDirector of Corporate Accounting & SEC Reporting